Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Neuroscience"
DOI: 10.1016/j.jocn.2017.01.007
Abstract: Isocitrate dehydrogenase 1 (IDH1) mutations in gliomas have been associated with a frontal lobe location and a greater proportion of noncontrast-enhancing tumour (nCET). The purpose of our study was to validate the utility of MRI… read more here.
Keywords: idh1 wildtype; glioblastoma; frontal lobe; idh1 ... See more keywords
BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-17062-1
Abstract: Isocitrate dehydrogenase 1 (IDH1)-wildtype glioblastoma (GBM) has found to be accompanied with increased expression of branched-chain amino acid trasaminase1 (BCAT1), which is associated with tumor growth and disease progression. In this retrospective study, quantitative RT-PCR, immunohistochemistry,… read more here.
Keywords: bcat1 level; wildtype; idh1 wildtype; wildtype glioblastoma ... See more keywords
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-oncology"
DOI: 10.1093/neuonc/noac197
Abstract: BACKGROUND IDH1/2 wildtype (IDHwt) glioma WHO grade 2 and 3 patients with pTERT mutation and/or EGFR amplification and/or +7/-10 chromosome gain/loss have a similar overall survival time as IDHwt glioblastoma patients, and are both considered… read more here.
Keywords: idh1 wildtype; glioblastoma; course; idhwt glioblastoma ... See more keywords